Both for HCL and the industry w e are seeing record high deal wins, but for the reasons well known it is not immediately translating into revenue growth trend. So, the question here is given the strong order backlog pipeline and the fact that some of these mega deals a re ramping up towards the latter half of FY’24, is it fair to assume FY’25 could be potentially a COVID period kind of high growth ye ar if the macro stays stable henceforth, ju st looking for your directional qualitative assessment, I appreciate that you don't give FY’25 guidance yet?
Questions across 21 calls
Sudheer Guntupalli
Kotak Mahindra AMC